Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis
CONCLUSIONS: Clinicians could use these factors to consider more aggressive treatment regimens for those at highest risk of early relapse.PMID:37393121 | DOI:10.1016/j.clml.2023.06.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 1, 2023 Category: Cancer & Oncology Authors: Salomon Manier Meletios Dimopoulos Cyrille Hulin Xavier Leleu Michel Delforge Katja Weisel Jorge Mouro Bruno Costa Michael Sturniolo Thierry Facon Source Type: research
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies
CONCLUSION: Selinexor-based regimens may offer effective and well-tolerated therapy to patients with relapsed and/or refractory MM who had disease previously exposed or refractory to αCD38 mAb therapy and could help address the unmet clinical need in these high-risk patients.PMID:37393120 | DOI:10.1016/j.clml.2023.06.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 1, 2023 Category: Cancer & Oncology Authors: Gary J Schiller Brea C Lipe Nizar J Bahlis Sascha A Tuchman William I Bensinger Heather J Sutherland Suzanne Lentzsch Muhamed Baljevic Darrell White Rami Kotb Christine I Chen Adriana Rossi Noa Biran Richard LeBlanc Sebastian Grosicki Maurizio Martelli Eb Source Type: research
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis
CONCLUSIONS: Clinicians could use these factors to consider more aggressive treatment regimens for those at highest risk of early relapse.PMID:37393121 | DOI:10.1016/j.clml.2023.06.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 1, 2023 Category: Cancer & Oncology Authors: Salomon Manier Meletios Dimopoulos Cyrille Hulin Xavier Leleu Michel Delforge Katja Weisel Jorge Mouro Bruno Costa Michael Sturniolo Thierry Facon Source Type: research
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies
CONCLUSION: Selinexor-based regimens may offer effective and well-tolerated therapy to patients with relapsed and/or refractory MM who had disease previously exposed or refractory to αCD38 mAb therapy and could help address the unmet clinical need in these high-risk patients.PMID:37393120 | DOI:10.1016/j.clml.2023.06.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 1, 2023 Category: Cancer & Oncology Authors: Gary J Schiller Brea C Lipe Nizar J Bahlis Sascha A Tuchman William I Bensinger Heather J Sutherland Suzanne Lentzsch Muhamed Baljevic Darrell White Rami Kotb Christine I Chen Adriana Rossi Noa Biran Richard LeBlanc Sebastian Grosicki Maurizio Martelli Eb Source Type: research
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis
CONCLUSIONS: Clinicians could use these factors to consider more aggressive treatment regimens for those at highest risk of early relapse.PMID:37393121 | DOI:10.1016/j.clml.2023.06.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 1, 2023 Category: Cancer & Oncology Authors: Salomon Manier Meletios Dimopoulos Cyrille Hulin Xavier Leleu Michel Delforge Katja Weisel Jorge Mouro Bruno Costa Michael Sturniolo Thierry Facon Source Type: research
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies
CONCLUSION: Selinexor-based regimens may offer effective and well-tolerated therapy to patients with relapsed and/or refractory MM who had disease previously exposed or refractory to αCD38 mAb therapy and could help address the unmet clinical need in these high-risk patients.PMID:37393120 | DOI:10.1016/j.clml.2023.06.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 1, 2023 Category: Cancer & Oncology Authors: Gary J Schiller Brea C Lipe Nizar J Bahlis Sascha A Tuchman William I Bensinger Heather J Sutherland Suzanne Lentzsch Muhamed Baljevic Darrell White Rami Kotb Christine I Chen Adriana Rossi Noa Biran Richard LeBlanc Sebastian Grosicki Maurizio Martelli Eb Source Type: research
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis
CONCLUSIONS: Clinicians could use these factors to consider more aggressive treatment regimens for those at highest risk of early relapse.PMID:37393121 | DOI:10.1016/j.clml.2023.06.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 1, 2023 Category: Cancer & Oncology Authors: Salomon Manier Meletios Dimopoulos Cyrille Hulin Xavier Leleu Michel Delforge Katja Weisel Jorge Mouro Bruno Costa Michael Sturniolo Thierry Facon Source Type: research
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies
CONCLUSION: Selinexor-based regimens may offer effective and well-tolerated therapy to patients with relapsed and/or refractory MM who had disease previously exposed or refractory to αCD38 mAb therapy and could help address the unmet clinical need in these high-risk patients.PMID:37393120 | DOI:10.1016/j.clml.2023.06.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 1, 2023 Category: Cancer & Oncology Authors: Gary J Schiller Brea C Lipe Nizar J Bahlis Sascha A Tuchman William I Bensinger Heather J Sutherland Suzanne Lentzsch Muhamed Baljevic Darrell White Rami Kotb Christine I Chen Adriana Rossi Noa Biran Richard LeBlanc Sebastian Grosicki Maurizio Martelli Eb Source Type: research
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis
CONCLUSIONS: Clinicians could use these factors to consider more aggressive treatment regimens for those at highest risk of early relapse.PMID:37393121 | DOI:10.1016/j.clml.2023.06.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 1, 2023 Category: Cancer & Oncology Authors: Salomon Manier Meletios Dimopoulos Cyrille Hulin Xavier Leleu Michel Delforge Katja Weisel Jorge Mouro Bruno Costa Michael Sturniolo Thierry Facon Source Type: research
Cross-Study Comparisons of JAK2 Inhibitors in Myelofibrosis: Risks and Recommendations
Clin Lymphoma Myeloma Leuk. 2023 Jun 9:S2152-2650(23)00186-6. doi: 10.1016/j.clml.2023.06.004. Online ahead of print.ABSTRACTWith multiple Janus Kinase (JAK) inhibitors approved or in late development for myelofibrosis, there is a logical desire in the field for comparative efficacy and safety data among these agents in order to inform treatment selection. However, due to the highly disparate nature of patient populations enrolled in different JAK inhibitor trials, as well as key differences in study design, any cross-study comparative analyses should be undertaken with a high degree of caution. Here, we show how differenc...
Source: Clinical Lymphoma and Myeloma - June 25, 2023 Category: Cancer & Oncology Authors: John Mascarenhas Ruben Mesa Source Type: research
Cross-Study Comparisons of JAK2 Inhibitors in Myelofibrosis: Risks and Recommendations
Clin Lymphoma Myeloma Leuk. 2023 Jun 9:S2152-2650(23)00186-6. doi: 10.1016/j.clml.2023.06.004. Online ahead of print.ABSTRACTWith multiple Janus Kinase (JAK) inhibitors approved or in late development for myelofibrosis, there is a logical desire in the field for comparative efficacy and safety data among these agents in order to inform treatment selection. However, due to the highly disparate nature of patient populations enrolled in different JAK inhibitor trials, as well as key differences in study design, any cross-study comparative analyses should be undertaken with a high degree of caution. Here, we show how differenc...
Source: Clinical Lymphoma and Myeloma - June 25, 2023 Category: Cancer & Oncology Authors: John Mascarenhas Ruben Mesa Source Type: research
Cross-Study Comparisons of JAK2 Inhibitors in Myelofibrosis: Risks and Recommendations
Clin Lymphoma Myeloma Leuk. 2023 Jun 9:S2152-2650(23)00186-6. doi: 10.1016/j.clml.2023.06.004. Online ahead of print.ABSTRACTWith multiple Janus Kinase (JAK) inhibitors approved or in late development for myelofibrosis, there is a logical desire in the field for comparative efficacy and safety data among these agents in order to inform treatment selection. However, due to the highly disparate nature of patient populations enrolled in different JAK inhibitor trials, as well as key differences in study design, any cross-study comparative analyses should be undertaken with a high degree of caution. Here, we show how differenc...
Source: Clinical Lymphoma and Myeloma - June 25, 2023 Category: Cancer & Oncology Authors: John Mascarenhas Ruben Mesa Source Type: research
Cross-Study Comparisons of JAK2 Inhibitors in Myelofibrosis: Risks and Recommendations
Clin Lymphoma Myeloma Leuk. 2023 Jun 9:S2152-2650(23)00186-6. doi: 10.1016/j.clml.2023.06.004. Online ahead of print.ABSTRACTWith multiple Janus Kinase (JAK) inhibitors approved or in late development for myelofibrosis, there is a logical desire in the field for comparative efficacy and safety data among these agents in order to inform treatment selection. However, due to the highly disparate nature of patient populations enrolled in different JAK inhibitor trials, as well as key differences in study design, any cross-study comparative analyses should be undertaken with a high degree of caution. Here, we show how differenc...
Source: Clinical Lymphoma and Myeloma - June 25, 2023 Category: Cancer & Oncology Authors: John Mascarenhas Ruben Mesa Source Type: research
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies
CONCLUSION: These analyses demonstrate a consistent benefit for melflufen and dexamethasone in patients with relapsed/refractory multiple myeloma who have not received an ASCT or progressed >36 months after receiving an ASCT (ClinicalTrials.gov identifier: NCT03151811).PMID:37355418 | DOI:10.1016/j.clml.2023.05.004 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 24, 2023 Category: Cancer & Oncology Authors: Pieter Sonneveld Paul G Richardson Heinz Ludwig Meletios-Athanasios Dimopoulos Fredrik H Schjesvold Roman H ájek Haifaa Abdulhaq Marcus Thuresson Stefan Norin Nicolaas A Bakker Maria-Victoria Mateos Source Type: research
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies
CONCLUSION: These analyses demonstrate a consistent benefit for melflufen and dexamethasone in patients with relapsed/refractory multiple myeloma who have not received an ASCT or progressed >36 months after receiving an ASCT (ClinicalTrials.gov identifier: NCT03151811).PMID:37355418 | DOI:10.1016/j.clml.2023.05.004 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 24, 2023 Category: Cancer & Oncology Authors: Pieter Sonneveld Paul G Richardson Heinz Ludwig Meletios-Athanasios Dimopoulos Fredrik H Schjesvold Roman H ájek Haifaa Abdulhaq Marcus Thuresson Stefan Norin Nicolaas A Bakker Maria-Victoria Mateos Source Type: research
